ThinkCyte used the SLAS 2026 conference in Boston to intensify promotion of its Ghost Cytometry and VisionSort platforms for high-speed, label-free, AI-driven cell analysis. Across several LinkedIn updates, the company highlighted live booth demonstrations and pointed researchers to scientific posters focused on immune cell phenotyping and senescence biomarker discovery.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The VisionSort Morphometry work centers on phenotyping and sorting phagocytosing immune cells and conducting morphometric profiling to identify potential universal biomarkers of cellular senescence. These capabilities are positioned for applications in drug discovery, phenotypic screening, CRISPR workflows, and regenerative medicine, where deeper, image-based cell characterization is increasingly in demand.
ThinkCyte also promoted a seminar and extended on-site demo period for VisionSort at GSK’s Stevenage site, offering both virtual and in-person access in early 2026. The program will allow GSK-associated researchers to run their own samples, indicating a push to validate the technology in real-world pharma R&D environments and foster closer collaboration.
Commercially, the company appears focused on converting scientific interest at conferences and pharma sites into concrete pipeline opportunities and deployments. By emphasizing AI-enabled, label-free sorting and real-time analysis, ThinkCyte is targeting efficiency and data-depth needs in preclinical research, flow cytometry, and advanced cell analysis markets.
If its Ghost Cytometry and VisionSort platforms gain broader traction with academic and biopharma users, ThinkCyte could strengthen its competitive position in high-content cell analysis tools and expand recurring revenue from instruments, software, and services. Overall, the week underscored a coordinated go-to-market push built around technical validation, thought leadership, and deepening engagement with key industry stakeholders.